Q BioMed (Q BioMed) EPS (Basic) : $-0.08 (TTM As of Feb. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Q BioMed EPS (Basic)?

Q BioMed's basic earnings per share (Basic EPS) for the three months ended in Feb. 2023 was $-0.02. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Feb. 2023 was $-0.08.

Q BioMed's EPS (Diluted) for the three months ended in Feb. 2023 was $-0.02. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Feb. 2023 was $-0.08.

Q BioMed's EPS without NRI for the three months ended in Feb. 2023 was $-0.02. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Feb. 2023 was -0.09.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Q BioMed EPS (Basic) Historical Data

The historical data trend for Q BioMed's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q BioMed EPS (Basic) Chart

Q BioMed Annual Data

Trend

Nov13

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

EPS (Basic)

Get a 7-Day Free Trial

-0.67

-0.68

-0.65

-0.33

-0.08

Q BioMed Quarterly Data
	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23
EPS (Basic)	Get a 7-Day Free Trial															-0.08	-0.06	-0.03	0.03	-0.02

Q BioMed EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Q BioMed's Basic EPS for the fiscal year that ended in Nov. 2022 is calculated as

Basic EPS (A: Nov. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-2.052	-	1.442)	/	44.757
	=	-0.08

Q BioMed's Basic EPS for the quarter that ended in Feb. 2023 is calculated as

Basic EPS (Q: Feb. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-0.722	-	0.105)	/	108.730
	=	-0.01

EPS (Basic) for the trailing twelve months (TTM) ended in Feb. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.08

Q BioMed (OTCPK:QBIO) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Q BioMed EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Q BioMed's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Q BioMed (Q BioMed) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q BioMed Inc (OTCPK:QBIO) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

C/o Ortoli Rosenstadt LLP, 366 Madison Avenue, 3rd Floor, New York, NY, USA, 10017

Website

https://www.qbiomed.com

Q BioMed Inc is a biomedical acceleration and development company. It has a focus on licensing, acquiring, and providing strategic resources to life sciences and healthcare companies. The company intends to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare-related products, companies, and sectors. Generic Strontium Chloride Sr-89 Injection USP (Strontium-89) is a radioactive pharmaceutical injection to relieve bone pain in patients with painful skeletal metastases. It also has three development-stage products: QBM-001 for rare pediatric non-verbal autism spectrum disorder, Uttroside-B for liver cancer, and MAN 01 for glaucoma.

Executives

William S Rosenstadt	director, 10 percent owner, officer: Chief Legal Officer	ORTOLI ROSENSTADT LLP, 501 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Denis Corin	director, 10 percent owner, officer: Chief Executive Officer	10 MARKET STREET, SUITE 427, GRAND CAYMAN E9 KY1-9006
Rick Panicucci	director	501 MADISON STREET, 14TH FLOOR, NEW YORK NY 10022
Alan P Lindsay	10 percent owner	580 HORNBY STREET, FIFTH FLOOR, VANCOUVER BC CANADA V6C 2E7 A1